

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

### NICE Technology Appraisal No.267; Ivabradine for the treatment of chronic heart failure

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> <li>• Servier Laboratories (ivabradine)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Anticoagulation Europe</li> <li>• Arrhythmia Alliance</li> <li>• Atrial Fibrillation Association</li> <li>• Blood Pressure UK</li> <li>• British Cardiac Patients Association</li> <li>• Cardiomyopathy UK</li> <li>• Cardiovascular Care Partnership</li> <li>• Different Strokes</li> <li>• HEART UK</li> <li>• Muslim Council of Britain</li> <li>• Network of Sikh Organisations</li> <li>• Pumping Marvellous</li> <li>• Somerville Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Stroke Association</li> <li>• Thrombosis UK</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Society for Heart Failure</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• Vascular Society of Great Britain and Ireland</li> </ul>	<p><u>General commentators</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> <li>• All Wales Therapeutics and Toxicology Centre</li> </ul> <p><u>Comparators</u></p> <ul style="list-style-type: none"> <li>• Aldosterone antagonists</li> <li>• Angiotensin-converting-enzyme (ACE) inhibitors</li> <li>• Angiotensin receptor blockers</li> <li>• Beta-blockers</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Circulation Foundation</li> <li>• MRC Clinical Trials Unit</li> <li>• National Centre for Cardiovascular Preventions and Outcomes</li> <li>• National Institute for Health Research</li> </ul>

<p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• Welsh Government</li> <li>• NHS Aylesbury Vale CCG</li> <li>• NHS Coastal West Sussex CCG</li> </ul>	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

**MTA Definitions:**

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.